BioSpace News Archive

Varex Imaging Corporation announced that management is scheduled to present at the Jefferies Healthcare Conference.

Defender Pharmaceuticals, Inc. (the “Company” or “Defender”), a privately held life sciences company based in St. Louis, today announced positive results from the Company’s pivotal phase III clinical trial of intranasally administered DPI-386 Nasal Gel (scopolamine HBr), which is in late-stage development for the prevention of nausea and vomiting induced by motion.

Hospital for Special Surgery, the world’s leading academic medical center focused on musculoskeletal health, will honor Frank P. Cammisa, Jr., MD, chief emeritus of HSS Spine, and Joe and Clara Wu Tsai, business leaders, philanthropists, and owners of the Brooklyn Nets and the New York Liberty, at its 38th Tribute Dinner on Monday, June 5.

Dante Genomics announced the launch of its Rare Disease Health Package to revolutionize rare disease diagnosis with whole genome sequencing testing.

The American Headache Society® (AHS), a professional society of healthcare providers dedicated to the study and treatment of headache and face pain, will host its 2023 Annual Scientific Meeting on June 15-18.

Vycellix, Inc. today announced that its founding Chairman & CEO, Evren Alici, M.D., Ph.D., presented pre-clinical, proof-of-concept results for the Company’s single-step approach to engineer allogeneic cells (VY-UC) at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting in Paris.

Legend Biotech Corporation announced that results from the Phase 3 CARTITUDE-4 study showed that, at a median follow up of 16 months, cilta-cel reduced the risk of disease progression or death by 74 percent compared to standard of care regimens in adult patients with multiple myeloma who have received one to three prior lines of therapy and are refractory to lenalidomide.

BioMark’s blood-based metabolomic biomarker panel clinically improved early-stage lung cancer detection through stage shifting.

Kite, a Gilead Company (Nasdaq: GILD), today announces detailed results from the overall survival (OS) analysis of the landmark Phase 3 ZUMA-7 study of Yescarta® (axicabtagene ciloleucel [axi-cel]) CAR T-cell therapy compared with historical standard of care (SOC) as initial treatment in the curative setting for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL).

Paragon operates an industry-leading geochemistry lab strategically located near Reno, Nevada, at the heart of one of the world’s most active mining regions